Ryan Sullivan, MD | Authors


Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma

October 03, 2019

Ryan Sullivan, MD, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.